Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BIOMARIN PHARMACEUTICAL INC.

(BMRN)
  Report
Delayed Nasdaq  -  04:00 2022-12-05 pm EST
103.53 USD   -1.92%
11/29Jefferies Adjusts BioMarin Pharmaceutical's Price Target to $120 From $100, Keeps Buy Rating
MT
11/24BioMarin Announces Advancements in FDA Review of ROCTAVIAN for Adults with Severe Hemophilia A
AQ
11/23Sector Update: Health Care Stocks Advancing Wednesday Afternoon
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2022 11/30/2022 12/01/2022 12/02/2022 12/05/2022 Date
97.12(c) 100.98(c) 103.02(c) 105.56(c) 103.53(c) Last
1 304 257 2 493 125 2 013 886 2 220 168 994 347 Volume
-1.56% +3.97% +2.02% +2.47% -1.92% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 2 094 M - -
Net income 2022 129 M - -
Net cash position 2022 500 M - -
P/E ratio 2022 154x
Yield 2022 -
Sales 2023 2 556 M - -
Net income 2023 291 M - -
Net cash position 2023 810 M - -
P/E ratio 2023 67,4x
Yield 2023 -
Capitalization 19 618 M 19 618 M -
EV / Sales 2022 9,13x
EV / Sales 2023 7,36x
Nbr of Employees 3 045
Free-Float 99,3%
More Financials
Company
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin 's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq... 
Sector
Pharmaceuticals
Calendar
02/22Earnings Release
More about the company
Ratings of BioMarin Pharmaceutical Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about BIOMARIN PHARMACEUTICAL INC.
11/29Jefferies Adjusts BioMarin Pharmaceutical's Price Target to $120 From $100, Keeps Buy R..
MT
11/24BioMarin Announces Advancements in FDA Review of ROCTAVIAN for Adults with Severe Hemop..
AQ
11/23Sector Update: Health Care Stocks Advancing Wednesday Afternoon
MT
11/23Sector Update: Health Care Stocks Still Advancing in Wednesday Trading
MT
11/23BioMarin Pharmaceutical Says US FDA No Longer Holding Meeting to Discuss Application fo..
MT
11/23BioMarin : FDA Drops Plans for AdCom Meeting on Hemophilia A Drug
DJ
11/23BioMarin Pharmaceutical Says FDA Cancels Advisory Meeting for Company's Biologics Licen..
MT
11/23BioMarin Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxapa..
PR
11/23BioMarin Pharmaceutical Inc. Announces Advancements in FDA Review of ROCTAVIAN™ (V..
CI
11/16Transcript : BioMarin Pharmaceutical Inc. Presents at 13th Annual Jefferies L..
CI
11/08Transcript : BioMarin Pharmaceutical Inc. Presents at Credit Suisse 31st Annu..
CI
11/08BioMarin Announces Incremental Progress on Biologics License Application Review for Val..
AQ
11/07BioMarin Announces Incremental Progress on Biologics License Application (BLA) Review f..
PR
11/07BioMarin Pharmaceutical Inc. Announces Incremental Progress on Biologics License Applic..
CI
11/04Insider Sell: Biomarin Pharmaceutical
MT
More news
News in other languages on BIOMARIN PHARMACEUTICAL INC.
11/23Mise à jour sectorielle : Les actions du secteur de la santé pro..
11/23Mise à jour sectorielle : Les actions du secteur de la santé pro..
11/23BioMarin Pharmaceutical déclare que la FDA américaine ne tient plus de réunion pour dis..
11/23BioMarin Pharmaceutical Inc. annonce des progrès dans l'examen par la FDA de ROCTAVIAN&..
11/07BioMarin Pharmaceutical Inc. annonce des progrès progressifs dans l'examen de la demand..
More news
Analyst Recommendations on BIOMARIN PHARMACEUTICAL INC.
More recommendations
ETFs positioned on BIOMARIN PHARMACEUTICAL INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Global X Genomics & Biotechnology ETF - USD4.35%5.06%NC
Volshares Large Cap ETF - USD4%0.02%United_States
First Trust NYSE Arca Biotechnology - Acc - USD3.78%2.59%-United_States
First Trust NYSE Arca Biotechnology Index F...2.95%4.16%United_States
VanEck Vectors Biotech ETF - USD2.82%2.85%United_States
More ETFs positioned on BIOMARIN PHARMACEUTICAL INC.
Chart BIOMARIN PHARMACEUTICAL INC.
Duration : Period :
BioMarin Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOMARIN PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Last Close Price 103,53 $
Average target price 115,45 $
Spread / Average Target 11,5%
EPS Revisions
Managers and Directors
Jean-Jacques BienaimÚ Chairman & Chief Executive Officer
Brian R. Mueller Chief Financial Officer & Executive VP-Finance
Henry J. Fuchs President-Worldwide Research & Development
Eduardo E. von Pervieux Chief Information Officer
C. Greg Guyer Chief Technical Officer & Executive Vice President
Sector and Competitors